Idazoxan hydrochloride |
| Catalog No.GC15813 |
Idazoxan hydrochloride (RX 781094 hydrochloride) is an α2-adrenoceptor antagonist and also an antagonist of imidazoline receptors (IRs).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 79944-56-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Idazoxan hydrochloride (RX 781094 hydrochloride, IDA) is a ligand for α2-adrenergic and imidazoline receptors with a molecular weight of 241. It binds to mitochondrial membranes and promotes apoptosis in pancreatic β cells[1]. Additionally, it competitively antagonizes the central hypotensive effects of imidazoline-like active molecules (IMs) [2]. It's worth noting that Idazoxan hydrochloride has been reported to improve motor symptoms in Parkinson's disease, levodopa-induced motor disturbances, and experimental Parkinson's syndrome.
In vitro studies demonstrate that incubating rat glioma C6 cells with 10 μM Idazoxan hydrochloride for 5 days leads to a 23% reduction in β-adrenergic receptor numbers and a 37% decrease in isoproterenol-induced cAMP accumulation[5]. Furthermore, Idazoxan hydrochloride exhibits cytotoxicity at concentrations of 0.05-1.0 mg/ml against mouse lung cancer cells (3LL) and human prostate cancer cells (DU-145), as well as other cancer cell lines including breast, gastric, ovarian, and non-Hodgkin's lymphoma[1].
Idazoxan hydrochloride has shown efficacy in reversing fluphenazine-induced catalepsy in male CD-COBS rats when subcutaneously injected at doses ranging from 0.16 to 5 mg/kg for a duration of 1 hour, with an ED50 of 0.25 mg/kg[3]. Intrathecal injection of Idazoxan hydrochloride (30 µg/10 µL) in SNL6W rats can enhance the endogenous analgesic index NSIA following 7,8-DHF treatment[4].
[1]. GF Eilon, L Weisenthal, M Stupecky,et al. Antineoplastic activity of idazoxan hydrochloride.[J]. Cancer Chemotherapy and Pharmacology,2009(64),1157-1163.
[2]. Bousquet P, et al. Participation of imidazoline receptors and alpha(2-)-adrenoceptors in the central hypotensive effects of imidazoline-like drugs. Ann N Y Acad Sci. 1999 Jun 21;881:272-8.
[3]. Roberto W Invernizzi, et al. The α2-Adrenoceptor Antagonist Idazoxan Reverses Catalepsy Induced by Haloperidol in Rats Independent of Striatal Dopamine Release: Role of Serotonergic Mechanisms. Neuropsychopharmacology volume 28, 2003: 872-879.
[4]. Kato D , Suto T , Obata H ,et al. Spinal Activation of Tropomyosin Receptor Kinase-B Recovers the Impaired Endogenous Analgesia in Neuropathic Pain Rats.[J].Anesth Analg, 2019(2).
[5]. Manji H K , Chen G , Bitran J A ,et al. Idazoxan down-regulates beta-adrenoceptors on C6 glioma cells in vitro.[J].European Journal of Pharmacology Molecular Pharmacology, 1992, 227(3):275-282.
Average Rating: 5 (Based on Reviews and 21 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *